Policy Watch: 25 Regulatory Updates — March 12, 2026

Schedules of Controlled Substances: Placement of Butonitazene, Flunitazene, and Metodesnitazene in Schedule I

This DEA action schedules three synthetic opioids but does not directly affect cannabis regulation; however, clinicians may consider implications for patients using multiple controlled substances.

Schedules of Controlled Substances: Placement of Ethylphenidate in Schedule I

# Regulatory Summary This action schedules ethylphenidate (a stimulant) as a controlled substance, establishing regulatory precedent for classifying synthetic drugs but does not directly affect cannabis medical practice or patient access.

Schedules of Controlled Substances: Temporary Placement of N-pyrrolidino metonitazene and N-pyrrolidino protonitazene in Schedule I

This DEA action temporarily places two synthetic opioids in Schedule I but does not directly affect cannabis regulation, scheduling, or clinical practice.

Importer of Controlled-Biopharmaceutical(2024-20085)DEA1425

# Regulatory Summary DEA authorization for controlled-biopharmaceutical importation establishes compliance pathways for cannabis-derived pharmaceutical products, enabling clinicians to access regulated medicinal cannabis formulations meeting pharmaceutical standards.

Schedules of Controlled Substances: Temporary Placement of N-Desethyl Isotonitazene and N-Piperidinyl Etonitazene in Schedule I

This regulatory action schedules synthetic opioids, not cannabis compounds, and has no direct relevance to cannabis clinicians or patients unless they simultaneously treat opioid use disorders.

Schedules of Controlled Substances: Rescheduling of Marijuana

# Regulatory Summary The DEA’s proposed rescheduling of marijuana from Schedule I to Schedule III would reduce federal restrictions on cannabis research and potentially increase patient access while simplifying prescribing for healthcare providers.

Definition of Engaged in the Business as a Dealer in Firearms

This firearms regulation defines dealer licensing requirements and has no direct relevance to cannabis clinicians or patients, as it addresses federal firearm commerce rather than cannabis medical practice or treatment.

Schedules of Controlled Substances: Placement of Etodesnitazene, N-Pyrrolidino etonitazene, and Protonitazene in Schedule I

This regulation places three opioid-like synthetic compounds in Schedule I, restricting their medical use; it is relevant to cannabis clinicians as an example of DEA scheduling that may inform discussions about alternative pain management approaches.

Schedules of Controlled Substances: Placement of Butonitazene, Flunitazene, and Metodesnitazene Substances in Schedule I

This regulatory action schedules synthetic opioids in Schedule I but does not directly affect cannabis medical practice, though clinicians should monitor potential drug interactions if patients use multiple controlled substances.

Schedules of Controlled Substances: Placement of 2-Methyl AP-237 in Schedule I

# Regulatory Summary The DEA placed 2-Methyl AP-237, a synthetic opioid, into Schedule I; this action is not directly relevant to cannabis medicine or clinical practice.

Schedules of Controlled Substances: Placement of 2,5-dimethoxy-4-iodoamphetamine and 2,5-dimethoxy-4-chloroamphetamine in Schedule I

This regulatory action schedules synthetic amphetamines, not cannabis compounds, and has minimal direct relevance to cannabis clinicians or patients beyond general controlled substance regulatory frameworks.

Schedules of Controlled Substances: Temporary Placement of MDMB–4en–PINACA, 4F–MDMB–BUTICA, ADB–4en–PINACA, CUMYL–PEGACLONE, 5F–EDMB–PICA, and MMB–FUBICA into Schedule I

The DEA temporarily scheduled six synthetic cannabinoids into Schedule I, restricting their legal use and potentially affecting cannabis clinicians’ understanding of unregulated cannabinoid products patients may encounter.

Schedules of Controlled Substances: Placement of Ethylphenidate in Schedule I

# Regulatory Summary This action schedules ethylphenidate as a controlled substance, which has minimal direct relevance to cannabis medicine but establishes DEA classification precedent for synthetic compounds affecting practitioner prescribing authority.

Schedules of Controlled Substances: Placement of Metonitazene in Schedule I

The DEA placed metonitazene, a synthetic opioid, into Schedule I, establishing it as a controlled substance with no accepted medical use—relevant to cannabis clinicians treating pain patients as an alternative therapeutic option.

Schedules of Controlled Substances: Temporary Placement ofEtizolam, Flualprazolam, Clonazolam, Flubromazolam, and Diclazepam in Schedule I

# Regulatory Summary This action temporarily schedules five benzodiazepine analogues as Schedule I controlled substances, relevant to cannabis clinicians managing patients using these substances concurrently or as alternative treatments.

Importer of Controlled Substances Application Biopharmaceutical Research Company – DEA1224

# Regulatory Summary A biopharmaceutical research company applied for DEA authorization to import controlled substances, enabling clinical research and development of cannabis-derived medicines under federal regulatory oversight.

Importer of Controlled-Bright Green(2024-20083)DEA1426

# Regulatory Summary DEA registration 2024-20083 authorizes an importer to handle controlled substances, potentially affecting cannabis medicine availability and supply chain compliance for clinical practitioners and patients.

Importer of Controlled-Cambridge Isotope(2024-20082)DEA1429

# Regulatory Summary DEA permit 2024-20082 authorizes Cambridge Isotope as a controlled substance importer, relevant to cannabis clinicians and patients through potential supply of labeled cannabinoid research compounds for clinical studies and therapeutic development.

Medicare and Medicaid Programs: Calendar Year 2025 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; etc.

CMS updates 2025 Medicare Part B payment policies and physician fee schedules; impacts reimbursement rates for covered services but does not directly address cannabis medicine coverage or payment.

Medicare and Medicaid Programs; CY 2025 Payment Policies under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; Medicare Prescription Drug Inflation Rebate Program (CMS-1807-P)

# Regulatory Summary This CMS proposed rule updates Medicare/Medicaid payment policies and coverage requirements under the Physician Fee Schedule for 2025, potentially affecting reimbursement determinations for cannabis-related medical services and clinician compensation structures.

Bulk Manufacturer-Royal Emerald (2024-11786) DEA1368

DEA registration approval for Royal Emerald as a bulk cannabis manufacturer, enabling licensed production and supply of cannabis products for clinical and patient use under federal regulatory oversight.

Importer Controlled-VA Cooperative (2024-11795) DEA1374

# Regulatory Summary DEA Form 1374 enables licensed importers to obtain controlled substances including cannabis derivatives for medical research and clinical use under DEA oversight and cooperative agreements.

Importer Controlled- Quagen Pharma (2024-11892) DEA1381

# Regulatory Summary DEA Form 1381 application for Quagen Pharma’s cannabis importer registration under controlled substance regulations, directly affecting legal cannabis product sourcing and availability for clinical practice.

Exempt Chemical Preparations May 2024 (2024-10465) – DEA372

# Regulatory Summary The DEA’s May 2024 exemption updates which chemical preparations avoid Schedule I controlled substance regulations, potentially affecting cannabis-derived pharmaceutical formulations’ regulatory classification and clinical accessibility.

Medicare and Medicaid Programs; CY 2024 Payment Policies under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; Continued Implementation of Requirements for Manufacturers of Certain Single-dose Container or Single-use Package Drugs to Provide Refunds with Respect to Discarded Amounts; Medicare Advantage (CMS-1784-F)

This CMS final rule establishes 2024 Medicare/Medicaid payment policies; cannabis remains federally non-covered, making this rule irrelevant to cannabis clinicians or patients.

# Clinical Perspective These regulatory actions reflect the ongoing challenge of synthetic drug proliferation, wherein manufacturers continuously modify chemical structures of opioids, stimulants, and benzodiazepines to evade scheduling restrictions. The predominance of nitazene analogs and designer benzodiazepines among these placements suggests a particular public health concern around novel synthetic opioids and illicit anxiolytics entering the illicit drug supply. From a clinical standpoint, these scheduling efforts attempt to address emerging substances of abuse, though the rapid pace of chemical modification often outpaces regulatory response, creating treatment and harm reduction challenges for clinicians managing patients with polysubstance use involving these compounds.